Clinical Trial Update: The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity [Phase 4]

View source ↗

Summary

A completed Phase 4 clinical trial examining how CYP8B1 genetic variations influence biochemical pathways affected by SGLT2 inhibitors in individuals with Type …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Erbil Polytechnic University | Conditions: Type 2 Diabetes, Obese Diabetics | Phase 4 | Status: COMPLETED